Gestational diabetes mellitus (GDM), one of the major pregnancy-related complications, characterized as a transitory form of diabetes induced by insulin resistance accompanied by a low/absent pancreatic beta-cell compensatory adaptation to the increased insulin demand, causes the acute, long-term, and transgenerational health complications. The aim of the study was to assess if alterations in gene expression of microRNAs associated with diabetes/cardiovascular/cerebrovascular diseases are present in whole peripheral blood of children aged 3-11 years descending from GDM complicated pregnancies. A substantially altered microRNA expression profile was found in children descending from GDM complicated pregnancies. Almost all microRNAs with the exception of miR-92a-3p, miR-155-5p, and miR-210-3p were upregulated. The microRNA expression profile also differed between children after normal and GDM complicated pregnancies in relation to the presence of overweight/obesity, prehypertension/hypertension, and/or valve problems and heart defects. Always, screening based on the combination of microRNAs was superior over using individual microRNAs, since at 10.0% false positive rate it was able to identify a large proportion of children with an aberrant microRNA expression profile (88.14% regardless of clinical findings, 75.41% with normal clinical findings, and 96.49% with abnormal clinical findings). In addition, the higher incidence of valve problems and heart defects was found in children with a prior exposure to GDM. The extensive file of predicted targets of all microRNAs aberrantly expressed in children descending from GDM complicated pregnancies indicates that a large group of these genes is involved in ontologies of diabetes/cardiovascular/cerebrovascular diseases. In general, children with a prior exposure to GDM are at higher risk of later development of diabetes mellitus and cardiovascular/cerebrovascular diseases, and would benefit from dispensarisation as well as implementation of primary prevention strategies.

Department of Molecular Biology and Cell Pathology 3rd Faculty of Medicine Charles University 10000 Prague Czech Republic

Institute for the Care of the Mother and Child 3rd Faculty of Medicine Charles University 14700 Prague Czech Republic

Zobrazit více v PubMed

American Diabetes Association Gestational diabetes mellitus. Diabetes Care. 2004;27:S88–S90. doi: 10.2337/diacare.27.2007.S88. PubMed DOI

International Diabetes Federation IDF Diabetes Atlas–Across the Globe. [(accessed on 12 April 2020)];2017 Available online: http://diabetesatlas.org/across-the-globe.html.

Bowes S.B., Hennessy T.R., Umpleby A.M., Benn J.J., Jackson N.C., Boroujerdi M.A., Sönksen P.H., Lowy C. Measurement of glucose metabolism and insulin secretion during normal pregnancy and pregnancy complicated by gestational diabetes. Diabetologia. 1996;39:976–983. doi: 10.1007/BF00403918. PubMed DOI

Di Cianni G., Miccoli R., Volpe L., Lencioni C., Del Prato S. Intermediate metabolism in normal pregnancy and in gestational diabetes. Diabetes Metab. Res. Rev. 2003;19:259–270. doi: 10.1002/dmrr.390. PubMed DOI

Barbour L.A., McCurdy C.E., Hernandez T.L., Kirwan J.P., Catalano P.M., Friedman J.E. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care. 2007;30:S112–S119. doi: 10.2337/dc07-s202. Corrected in Diabetes Care2007, 30, 3154. PubMed DOI

Chen X.Y., Li G.M., Dong Q., Peng H. MiR-577 inhibits pancreatic β-cell function and survival by targeting fibroblast growth factor 21 (FGF-21) in pediatric diabetes. Genet. Mol. Res. 2015;14:15462–15470. doi: 10.4238/2015.November.30.24. PubMed DOI

Dias S., Pheiffer C., Abrahams Y., Rheeder P., Adam S. Molecular Biomarkers for Gestational Diabetes Mellitus. Int. J. Mol. Sci. 2018;19:2926. doi: 10.3390/ijms19102926. PubMed DOI PMC

Zhao C., Dong J., Jiang T., Shi Z., Yu B., Zhu Y., Chen D., Xu J., Huo R., Dai J., et al. Early Second-Trimester Serum miRNA Profiling Predicts Gestational Diabetes Mellitus. PLoS ONE. 2011;6:e23925. doi: 10.1371/journal.pone.0023925. PubMed DOI PMC

Zhu Y., Tian F., Li H., Zhou Y., Lu J., Ge Q. Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus. Int. J. Gynaecol. Obstet. 2015;130:49–53. doi: 10.1016/j.ijgo.2015.01.010. PubMed DOI

Tryggestad J.B., Vishwanath A., Jiang S., Mallappa A., Teague A.M., Takahashi Y., Thompson D.M., Chernausek S.D. Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. Clin. Sci. 2016;130:1955–1967. doi: 10.1042/CS20160305. PubMed DOI PMC

Poirier C., Desgagné V., Guérin R., Bouchard L. MicroRNAs in Pregnancy and Gestational Diabetes Mellitus: Emerging Role in Maternal Metabolic Regulation. Curr. Diabetes Rep. 2017;17:35. doi: 10.1007/s11892-017-0856-5. PubMed DOI

Wander P.L., Boyko E.J., Hevner K., Parikh V.J., Tadesse M.G., Sorensen T.K., Williams M.A., Enquobahrie D.A. Circulating early- and mid-pregnancy microRNAs and risk of gestational diabetes. Diabetes Res. Clin. Pract. 2017;132:1–9. doi: 10.1016/j.diabres.2017.07.024. PubMed DOI PMC

Cao Y.L., Jia Y.J., Xing B.H., Shi D.D., Dong X.J. Plasma microRNA-16-5p, -17-5p and -20a-5p: Novel diagnostic biomarkers for gestational diabetes mellitus. J. Obstet. Gynaecol. Res. 2017;43:974–981. doi: 10.1111/jog.13317. PubMed DOI

Sebastiani G., Guarino E., Grieco G.E., Formichi C., Poggi C.D., Ceccarelli E., Dotta F. Circulating microRNA (miRNA) Expression Profiling in Plasma of Patients with Gestational Diabetes Mellitus Reveals Upregulation of miRNA miR-330-3p. Front. Endocrinol. 2017;8:345. doi: 10.3389/fendo.2017.00345. PubMed DOI PMC

Stirm L., Huypens P., Sass S., Batra R., Fritsche L., Brucker S., Abele H., Hennige A.M., Theis F., Beckers J., et al. Maternal Whole Blood Cell miRNA-340 Is Elevated in Gestational Diabetes and Inversely Regulated by Glucose and Insulin. Sci. Rep. 2018;8:1366. doi: 10.1038/s41598-018-19200-9. PubMed DOI PMC

He Y., Bai J., Liu P., Dong J., Tang Y., Zhou J., Han P., Xing J., Chen Y., Yu X. miR-494 Protects Pancreatic β-cell Function by Targeting PTEN in Gestational Diabetes Mellitus. EXCLI J. 2017;16:1297–1307. PubMed PMC

Pheiffer C., Dias S., Rheeder P., Adam S. Decreased Expression of Circulating miR-20a-5p in South African Women with Gestational Diabetes Mellitus. Mol. Diagn. Ther. 2018;22:345–352. doi: 10.1007/s40291-018-0325-0. PubMed DOI

Tagoma A., Alnek K., Kirss A., Uibo R., Haller-Kikkatalo K. MicroRNA profiling of second trimester maternal plasma shows upregulation of miR-195-5p in patients with gestational diabetes. Gene. 2018;672:137–142. doi: 10.1016/j.gene.2018.06.004. PubMed DOI

Lamadrid-Romero M., Solís K.H., Cruz-Reséndiz M.S., Pérez J.E., Díaz N.F., Flores-Herrera H., García-López G., Perichart O., Reyes-Muñoz E., Arenas-Huertero F., et al. Central nervous system development-related microRNAs levels increase in the serum of gestational diabetic women during the first trimester of pregnancy. Neurosci. Res. 2018;130:8–22. doi: 10.1016/j.neures.2017.08.003. PubMed DOI

Hocaoglu M., Demirer S., Senturk H., Turgut A., Komurcu-Bayrak E. Differential expression of candidate circulating microRNAs in maternal blood leukocytes of the patients with preeclampsia and gestational diabetes mellitus. Pregnancy Hypertens. 2019;17:5–11. doi: 10.1016/j.preghy.2019.04.004. PubMed DOI

Yoffe L., Polsky A., Gilam A., Raff C., Mecacci F., Ognibene A., Crispi F., Gratacós E., Kanety H., Mazaki-Tovi S., et al. Early Diagnosis of Gestational Diabetes Mellitus Using Circulating microRNAs. Eur. J. Endocrinol. 2019;181:565–577. doi: 10.1530/EJE-19-0206. PubMed DOI

Kawasaki M., Arata N., Miyazaki C., Mori R., Kikuchi T., Ogawa Y., Ota E. Obesity and abnormal glucose tolerance in offspring of diabetic mothers: A systematic review and meta-analysis. PLoS ONE. 2018;13:e0190676. doi: 10.1371/journal.pone.0190676. PubMed DOI PMC

Garcia-Vargas L., Addison S.S., Nistala R., Kurukulasuriya D., Sowers J.R. Gestational Diabetes and the Offspring: Implications in the Development of the Cardiorenal Metabolic Syndrome in Offspring. Cardiorenal Med. 2012;2:134–142. doi: 10.1159/000337734. PubMed DOI PMC

Hammoud N.M., Visser G.H.A., van Rossem L., Biesma D.H., Wit J.M., de Valk H.W. Long-term BMI and growth profiles in offspring of women with gestational diabetes. Diabetologia. 2018;61:1037–1045. doi: 10.1007/s00125-018-4584-4. PubMed DOI PMC

Bianco M.E., Josefson J.L. Hyperglycemia During Pregnancy and Long-Term Offspring Outcomes. Curr. Diabetes Rep. 2020;19:143. doi: 10.1007/s11892-019-1267-6. PubMed DOI PMC

Lee H., Jang H.C., Park H.K., Cho N.H. Early manifestation of cardiovascular disease risk factors in offspring of mothers with previous history of gestational diabetes mellitus. Diabetes Res. Clin. Pract. 2007;78:238–245. doi: 10.1016/j.diabres.2007.03.023. PubMed DOI

Lu J., Zhang S., Li W., Leng J., Wang L., Liu H., Li W., Zhang C., Qi L., Tuomilehto J., et al. Maternal Gestational Diabetes Is Associated with Offspring’s Hypertension. Am. J. Hypertens. 2019;32:335–342. doi: 10.1093/ajh/hpz005. PubMed DOI PMC

Wright C.S., Rifas-Shiman S.L., Rich-Edwards J.W., Taveras E.M., Gillman M.W., Oken E. Intrauterine exposure to gestational diabetes, child adiposity, and blood pressure. Am. J. Hypertens. 2009;22:215–220. doi: 10.1038/ajh.2008.326. PubMed DOI PMC

Tam W.H., Ma R.C.W., Ozaki R., Li A.M., Chan M.H.M., Yuen L.Y., Lao T.T.H., Yang X., Ho C.S., Tutino G.E., et al. In Utero Exposure to Maternal Hyperglycemia Increases Childhood Cardiometabolic Risk in Offspring. Diabetes Care. 2017;40:679–686. doi: 10.2337/dc16-2397. PubMed DOI PMC

Lowe W.L., Jr., Scholtens D.M., Kuang A., Linder B., Lawrence J.M., Lebenthal Y., McCance D., Hamilton J., Nodzenski M., Talbot O., et al. HAPO Follow-up Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Gestational Diabetes Mellitus and Childhood Glucose Metabolism. Diabetes Care. 2019;42:372–380. doi: 10.2337/dc18-1646. PubMed DOI PMC

Tsadok M.A., Friedlander Y., Paltiel O., Manor O., Meiner V., Hochner H., Sagy Y., Sharon N., Yazdgerdi S., Siscovick D., et al. Obesity and blood pressure in 17-year-old offspring of mothers with gestational diabetes: Insights from the Jerusalem Perinatal Study. Exp. Diabetes Res. 2011;2011:906154. PubMed PMC

Perng W., Hockett C.W., Sauder K.A., Dabelea D. In utero exposure to gestational diabetes mellitus and cardiovascular risk factors in youth: A longitudinal analysis in the EPOCH cohort. Pediatr. Obes. 2020:e12611. doi: 10.1111/ijpo.12611. PubMed DOI PMC

Leybovitz-Haleluya N., Wainstock T., Landau D., Sheiner E. Maternal gestational diabetes mellitus and the risk of subsequent pediatric cardiovascular diseases of the offspring: A population-based cohort study with up to 18 years of follow up. Acta Diabetol. 2018;55:1037–1042. doi: 10.1007/s00592-018-1176-1. PubMed DOI

Yu Y., Arah O.A., Liew Z., Cnattingius S., Olsen J., Sørensen H.T., Qin G., Li J. Maternal diabetes during pregnancy and early onset of cardiovascular disease in offspring: Population based cohort study with 40 years of follow-up. BMJ. 2019;367:l6398. doi: 10.1136/bmj.l6398. PubMed DOI PMC

Franks P.W., Looker H.C., Kobes S., Touger L., Tataranni P.A., Hanson R.L., Knowler W.C. Gestational glucose tolerance and risk of type 2 diabetes in young Pima Indian offspring. Diabetes. 2006;55:460–465. doi: 10.2337/diabetes.55.02.06.db05-0823. PubMed DOI

Clausen T.D., Mathiesen E.R., Hansen T., Pedersen O., Jensen D.M., Lauenborg J., Damm P. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: The role of intrauterine hyperglycemia. Diabetes Care. 2008;31:340–346. doi: 10.2337/dc07-1596. PubMed DOI

Van Dam J.M., Garrett A.J., Schneider L.A., Hodyl N.A., Goldsworthy M.R., Coat S., Rowan J.A., Hague W.M., Pitcher J.B. Reduced Cortical Excitability, Neuroplasticity, and Salivary Cortisol in 11-13-Year-Old Children Born to Women with Gestational Diabetes Mellitus. EBioMedicine. 2018;31:143–149. doi: 10.1016/j.ebiom.2018.04.011. PubMed DOI PMC

Xiang A.H., Wang X., Martinez M.P., Getahun D., Page K.A., Buchanan T.A., Feldman K. Maternal Gestational Diabetes Mellitus, Type 1 Diabetes, and Type 2 Diabetes During Pregnancy and Risk of ADHD in Offspring. Diabetes Care. 2018;41:2502–2508. doi: 10.2337/dc18-0733. PubMed DOI

Nomura Y., Marks D.J., Grossman B., Yoon M., Loudon H., Stone J., Halperin J.M. Exposure to gestational diabetes mellitus and low socioeconomic status: Effects on neurocognitive development and risk of attention-deficit/hyperactivity disorder in offspring. Arch. Pediatr. Adolesc. Med. 2012;166:337–343. PubMed PMC

Xiang A.H., Wang X., Martinez M.P., Walthall J.C., Curry E.S., Page K., Buchanan T.A., Coleman K.J., Getahun D. Association of maternal diabetes with autism in offspring. JAMA. 2015;313:1425–1434. doi: 10.1001/jama.2015.2707. PubMed DOI

Xu G., Jing J., Bowers K., Liu B., Bao W. Maternal diabetes and the risk of autism spectrum disorders in the offspring: A systematic review and meta-analysis. J. Autism Dev. Disord. 2014;44:766–775. doi: 10.1007/s10803-013-1928-2. PubMed DOI PMC

Ornoy A., Wolf A., Ratzon N., Greenbaum C., Dulitzky M. Neurodevelopmental outcome at early school age of children born to mothers with gestational diabetes. Arch. Dis. Child. Fetal Neonatal Ed. 1999;81:F10–F14. doi: 10.1136/fn.81.1.F10. PubMed DOI PMC

Nahum Sacks K., Friger M., Shoham-Vardi I., Abokaf H., Spiegel E., Sergienko R., Landau D., Sheiner E. Prenatal exposure to gestational diabetes mellitus as an independent risk factor for long-term neuropsychiatric morbidity of the offspring. Am. J. Obstet. Gynecol. 2016;215:380e1–380e7. doi: 10.1016/j.ajog.2016.03.030. PubMed DOI

Walter E., Tsumi E., Wainstock T., Spiegel E., Sheiner E. Maternal gestational diabetes mellitus: Is it associated with long-term pediatric ophthalmic morbidity of the offspring? J. Maternal Fetal Neonatal Med. 2019;32:2529–2538. doi: 10.1080/14767058.2018.1439918. PubMed DOI

Martinez M.P., Lin J., Chow T., Chung J., Wang X., Xiang A.H. Maternal Gestational Diabetes and Type 2 Diabetes During Pregnancy and Risk of Childhood Asthma in Offspring. J. Pediatr. 2020;219:173–179. doi: 10.1016/j.jpeds.2019.12.053. PubMed DOI

Li J., Dong X., Wang Z., Wu J. MicroRNA-1 in Cardiac Diseases and Cancers. Korean J. Physiol. Pharmacol. 2014;18:359–363. doi: 10.4196/kjpp.2014.18.5.359. PubMed DOI PMC

Li Y.Q., Zhang M.F., Wen H.Y., Hu C.L., Liu R., Wei H.Y., Ai C.M., Wang G., Liao X.X., Li X. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics. 2013;68:75–80. doi: 10.6061/clinics/2013(01)OA12. PubMed DOI PMC

Gasiulė S., Stankevičius V., Patamsytė V., Ražanskas R., Zukovas G., Kapustina Z., Zaliaduonytė D., Benetis R., Lesauskaitė V., Vilkaitis G. Tissue-Specific miRNAs Regulate the Development of Thoracic Aortic Aneurysm: The Emerging Role of KLF4 Network. J. Clin. Med. 2019;8:1609. doi: 10.3390/jcm8101609. PubMed DOI PMC

Gerlinger-Romero F., Yonamine C.Y., Junior D.C., Esteves J.V., Machado U.F. Dysregulation between TRIM63/FBXO32 expression and soleus muscle wasting in diabetic rats: Potential role of miR-1-3p, -29a/b-3p, and -133a/b-3p. Mol. Cell Biochem. 2017;427:187–199. doi: 10.1007/s11010-016-2910-z. PubMed DOI

Kokkinopoulou I., Maratou E., Mitrou P., Boutati E., Sideris D.C., Fragoulis E.G., Christodoulou M.I. Decreased expression of microRNAs targeting type-2 diabetes susceptibility genes in peripheral blood of patients and predisposed individuals. Endocrine. 2019;66:226–239. doi: 10.1007/s12020-019-02062-0. PubMed DOI

Hromadnikova I., Kotlabova K., Dvorakova L., Krofta L. Evaluation of Vascular Endothelial Function in Young and Middle-Aged Women with Respect to a History of Pregnancy, Pregnancy-Related Complications, Classical Cardiovascular Risk Factors, and Epigenetics. Int. J. Mol. Sci. 2020;21:430. doi: 10.3390/ijms21020430. PubMed DOI PMC

Wang X., Shang Y., Dai S., Wu W., Yi F., Cheng L. MicroRNA-16-5p aggravates myocardial infarction injury by targeting expression of insulin receptor substrates 1 and mediating myocardial apoptosis and angiogenesis. Curr. Neurovascular Res. 2020;17:11–17. doi: 10.2174/1567202617666191223142743. PubMed DOI

O’Sullivan J.F., Neylon A., McGorrian C., Blake G.J. miRNA-93-5p and other miRNAs as predictors of coronary artery disease and STEMI. Int. J. Cardiol. 2016;224:310–316. doi: 10.1016/j.ijcard.2016.09.016. PubMed DOI

Vegter E.L., Schmitter D., Hagemeijer Y., Ovchinnikova E.S., van der Harst P., Teerlink J.R., O’Connor C.M., Metra M., Davison B.A., Bloomfield D., et al. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int. J. Cardiol. 2016;224:231–239. doi: 10.1016/j.ijcard.2016.09.010. PubMed DOI

Gacoń J., Badacz R., Stępień E., Karch I., Enguita F.J., Żmudka K., Przewłocki T., Kabłak-Ziembicka A. Diagnostic and prognostic micro-RNAs in ischaemic stroke due to carotid artery stenosis and in acute coronary syndrome: A four-year prospective study. Kardiol. Polska. 2018;76:362–369. doi: 10.5603/KP.a2017.0243. PubMed DOI

Duan Y.R., Chen B.P., Chen F., Yang S.X., Zhu C.Y., Ma Y.L., Li Y., Shi J. Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte. J. Cell Mol. Med. 2019 doi: 10.1111/jcmm.14558. PubMed DOI PMC

Assmann T.S., Recamonde-Mendoza M., Costa A.R., Puñales M., Tschiedel B., Canani L.H., Bauer A.C., Crispim D. Circulating miRNAs in diabetic kidney disease: Case-control study and in silico analyses. Acta Diabetol. 2019;56:55–65. doi: 10.1007/s00592-018-1216-x. PubMed DOI

Alicka M., Major P., Wysocki M., Marycz K. Adipose-Derived Mesenchymal Stem Cells Isolated from Patients with Type 2 Diabetes Show Reduced “Stemness” through an Altered Secretome Profile, Impaired Anti-Oxidative Protection, and Mitochondrial Dynamics Deterioration. J. Clin. Med. 2019;8:765. doi: 10.3390/jcm8060765. PubMed DOI PMC

Mogilyansky E., Rigoutsos I. The miR-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013;20:1603–1614. doi: 10.1038/cdd.2013.125. PubMed DOI PMC

Zhou L., Qi R.Q., Liu M., Xu Y.P., Li G., Weiland M., Kaplan D.H., Mi Q.S. microRNA miR-17-92 cluster is highly expressed in epidermal Langerhans cells but not required for its development. Genes Immun. 2014;15:57–61. doi: 10.1038/gene.2013.61. PubMed DOI

Danielson L.S., Park D.S., Rotllan N., Chamorro-Jorganes A., Guijarro M.V., Fernandez-Hernando C., Fishman G.I., Phoon C.K., Hernando E. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. FASEB J. 2013;27:1460–1467. doi: 10.1096/fj.12-221994. PubMed DOI PMC

Du W., Pan Z., Chen X., Wang L., Zhang Y., Li S., Liang H., Xu C., Zhang Y., Wu Y., et al. By targeting Stat3 microRNA-17-5p promotes cardiomyocyte apoptosis in response to ischemia followed by reperfusion. Cell Physiol. Biochem. 2014;34:955–965. doi: 10.1159/000366312. PubMed DOI

Kaucsár T., Révész C., Godó M., Krenács T., Albert M., Szalay C.I., Rosivall L., Benyó Z., Bátkai S., Thum T., et al. Activation of the miR-17 family and miR-21 during murine kidney ischemia-reperfusion injury. Nucleic Acid Ther. 2013;23:344–354. doi: 10.1089/nat.2013.0438. PubMed DOI PMC

Fang L., Ellims A.H., Moore X.L., White D.A., Taylor A.J., Chin-Dusting J., Dart A.M. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J. Transl. Med. 2015;13:314. doi: 10.1186/s12967-015-0672-0. PubMed DOI PMC

Wu J., Du K., Lu X. Elevated expressions of serum miR-15a, miR-16, and miR-17-5p are associated with acute ischemic stroke. Int. J. Clin. Exp. Med. 2015;8:21071–21079. PubMed PMC

Chen J., Xu L., Hu Q., Yang S., Zhang B., Jiang H. MiR-17-5p as circulating biomarkers for the severity of coronary atherosclerosis in coronary artery disease. Int. J. Cardiol. 2015;197:123–124. doi: 10.1016/j.ijcard.2015.06.037. PubMed DOI

Tian L., Song Z., Shao W., Du W.W., Zhao L.R., Zeng K., Yang B.B., Jin T. Curcumin represses mouse 3T3-L1 cell adipogenic differentiation via inhibiting miR-17-5p and stimulating the Wnt signalling pathway effector Tcf7l2. Cell Death Dis. 2017;8:e2559. doi: 10.1038/cddis.2016.455. PubMed DOI PMC

Chen T.C., Sung M.L., Kuo H.C., Chien S.J., Yen C.K., Chen C.N. Differential regulation of human aortic smooth muscle cell proliferation by monocyte-derived macrophages from diabetic patients. PLoS ONE. 2014;9:e113752. doi: 10.1371/journal.pone.0113752. PubMed DOI PMC

Mendell J.T. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008;133:217–222. doi: 10.1016/j.cell.2008.04.001. PubMed DOI PMC

Brock M., Samillan V.J., Trenkmann M., Schwarzwald C., Ulrich S., Gay R.E., Gassmann M., Ostergaard L., Gay S., Speich R., et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur. Heart J. 2014;35:3203–3211. doi: 10.1093/eurheartj/ehs060. PubMed DOI

Platania C.B.M., Maisto R., Trotta M.C., D’Amico M., Rossi S., Gesualdo C., D’Amico G., Balta C., Herman H., Hermenean A., et al. Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach. Br. J. Pharmacol. 2019;176:2179–2194. PubMed PMC

Lareyre F., Clément M., Moratal C., Loyer X., Jean-Baptiste E., Hassen-Khodja R., Chinetti G., Mallat Z., Raffort J. Differential micro-RNA expression in diabetic patients with abdominal aortic aneurysm. Biochimie. 2019;162:1–7. doi: 10.1016/j.biochi.2019.03.012. PubMed DOI

Dickinson B.A., Semus H.M., Montgomery R.L., Stack C., Latimer P.A., Lewton S.M., Lynch J.M., Hullinger T.G., Seto A.G., van Rooij E. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur. J. Heart Fail. 2013;15:650–659. doi: 10.1093/eurjhf/hft018. PubMed DOI

Flowers E., Aouizerat B.E., Abbasi F., Lamendola C., Grove K.M., Fukuoka Y., Reaven G.M. Circulating microRNA-320a and microRNA-486 predict thiazolidinedione response: Moving towards precision health for diabetes prevention. Metabolism. 2015;64:1051–1059. doi: 10.1016/j.metabol.2015.05.013. PubMed DOI PMC

Katayama M., Wiklander O.P.B., Fritz T., Caidahl K., El-Andaloussi S., Zierath J.R., Krook A. Circulating Exosomal miR-20b-5p Is Elevated in Type 2 Diabetes and Could Impair Insulin Action in Human Skeletal Muscle. Diabetes. 2019;68:515–526. doi: 10.2337/db18-0470. PubMed DOI

Xiong Y., Chen L., Yan C., Zhou W., Endo Y., Liu J., Hu L., Hu Y., Mi B., Liu G. Circulating Exosomal miR-20b-5p Inhibition Restores Wnt9b Signaling and Reverses Diabetes-Associated Impaired Wound Healing. Small. 2020;16:e1904044. doi: 10.1002/smll.201904044. PubMed DOI

Zhu K., Hu X., Chen H., Li F., Yin N., Liu A.L., Shan K., Qin Y.W., Huang X., Chang Q., et al. Downregulation of circRNA DMNT3B contributes to diabetic retinal vascular dysfunction through targeting miR-20b-5p and BAMBI. EBioMedicine. 2019;49:341–353. doi: 10.1016/j.ebiom.2019.10.004. PubMed DOI PMC

Sekar D., Venugopal B., Sekar P., Ramalingam K. Role of microRNA 21 in diabetes and associated/related diseases. Gene. 2016;582:14–18. doi: 10.1016/j.gene.2016.01.039. PubMed DOI

Suárez Y., Fernández-Hernando C., Pober J.S., Sessa W.C. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ. Res. 2007;100:1164–1173. doi: 10.1161/01.RES.0000265065.26744.17. PubMed DOI

Dong S., Ma W., Hao B., Hu F., Yan L., Yan X., Wang Y., Chen Z., Wang Z. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int. J. Clin. Exp. Pathol. 2014;7:565–574. PubMed PMC

Zhang J., Xing Q., Zhou X., Li J., Li Y., Zhang L., Zhou Q., Tang B. Circulating miRNA 21 is a promising biomarker for heart failure. Mol. Med. Rep. 2017;16:7766–7774. doi: 10.3892/mmr.2017.7575. PubMed DOI

Licholai S., Blaż M., Kapelak B., Sanak M. Unbiased Profile of MicroRNA Expression in Ascending Aortic Aneurysm Tissue Appoints Molecular Pathways Contributing to the Pathology. Ann. Thorac. Surg. 2016;102:1245–1252. doi: 10.1016/j.athoracsur.2016.03.061. PubMed DOI

Kriegel A.J., Baker M.A., Liu Y., Liu P., Cowley A.W., Jr., Liang M. Endogenous microRNAs in human microvascular endothelial cells regulate mRNAs encoded by hypertension-related genes. Hypertension. 2015;66:793–799. doi: 10.1161/HYPERTENSIONAHA.115.05645. PubMed DOI PMC

Velle-Forbord T., Eidlaug M., Debik J., Sæther J.C., Follestad T., Nauman J., Gigante B., Røsjø H., Omland T., Langaas M., et al. Circulating microRNAs as predictive biomarkers of myocardial infarction: Evidence from the HUNT study. Atherosclerosis. 2019;289:1–7. doi: 10.1016/j.atherosclerosis.2019.07.024. PubMed DOI

Demirsoy İ.H., Ertural D.Y., Balci Ş., Çınkır Ü., Sezer K., Tamer L., Aras N. Profiles of Circulating MiRNAs Following Metformin Treatment in Patients with Type 2 Diabetes. J. Med. Biochem. 2018;37:499–506. doi: 10.2478/jomb-2018-0009. PubMed DOI PMC

Olivieri F., Spazzafumo L., Bonafè M., Recchioni R., Prattichizzo F., Marcheselli F., Micolucci L., Mensà E., Giuliani A., Santini G., et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: Relationship with type 2 diabetes complications. Oncotarget. 2015;6:35372–35382. doi: 10.18632/oncotarget.6164. PubMed DOI PMC

Assmann T.S., Recamonde-Mendoza M., De Souza B.M., Crispim D. MicroRNA expression profiles and type 1 diabetes mellitus: Systematic review and bioinformatic analysis. Endocr. Connect. 2017;6:773–790. doi: 10.1530/EC-17-0248. PubMed DOI PMC

Lakhter A.J., Pratt R.E., Moore R.E., Doucette K.K., Maier B.F., DiMeglio L.A., Sims E.K. Beta cell extracellular vesicle miR-21-5p cargo is increased in response to inflammatory cytokines and serves as a biomarker of type 1 diabetes. Diabetologia. 2018;61:1124–1134. doi: 10.1007/s00125-018-4559-5. PubMed DOI PMC

Grieco G.E., Cataldo D., Ceccarelli E., Nigi L., Catalano G., Brusco N., Mancarella F., Ventriglia G., Fondelli C., Guarino E., et al. Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism. Noncoding RNA. 2018;4:37. doi: 10.3390/ncrna4040037. PubMed DOI PMC

Gholaminejad A., Abdul Tehrani H., Gholami Fesharaki M. Identification of candidate microRNA biomarkers in diabetic nephropathy: A meta-analysis of profiling studies. J. Nephrol. 2018;31:813–831. doi: 10.1007/s40620-018-0511-5. PubMed DOI

Long B., Gan T.Y., Zhang R.C., Zhang Y.H. miR-23a Regulates Cardiomyocyte Apoptosis by Targeting Manganese Superoxide Dismutase. Mol. Cells. 2017;40:542–549. doi: 10.14348/molcells.2017.0012. PubMed DOI PMC

Wang S., He W., Wang C. MiR-23a Regulates the Vasculogenesis of Coronary Artery Disease by Targeting Epidermal Growth Factor Receptor. Cardiovasc. Ther. 2016;34:199–208. doi: 10.1111/1755-5922.12187. PubMed DOI

Cong X., Li Y., Lu N., Dai Y., Zhang H., Zhao X., Liu Y. Resveratrol attenuates the inflammatory reaction induced by ischemia/reperfusion in the rat heart. Mol. Med. Rep. 2014;9:2528–2532. doi: 10.3892/mmr.2014.2090. PubMed DOI

Černá V., Ostašov P., Pitule P., Moláček J., Třeška V., Pešta M. The Expression Profile of MicroRNAs in Small and Large Abdominal Aortic Aneurysms. Cardiol. Res. Pract. 2019;2019:8645840. doi: 10.1155/2019/8645840. PubMed DOI PMC

Lozano-Bartolomé J., Llauradó G., Portero-Otin M., Altuna-Coy A., Rojo-Martínez G., Vendrell J., Jorba R., Rodríguez-Gallego E., Chacón M.R. Altered Expression of miR-181a-5p and miR-23a-3p Is Associated with Obesity and TNFα-Induced Insulin Resistance. J. Clin. Endocrinol. Metab. 2018;103:1447–1458. doi: 10.1210/jc.2017-01909. PubMed DOI

Dolz S., Górriz D., Tembl J.I., Sánchez D., Fortea G., Parkhutik V., Lago A. Circulating MicroRNAs as Novel Biomarkers of Stenosis Progression in Asymptomatic Carotid Stenosis. Stroke. 2017;48:10–16. doi: 10.1161/STROKEAHA.116.013650. PubMed DOI

De Gonzalo-Calvo D., Cenarro A., Garlaschelli K., Pellegatta F., Vilades D., Nasarre L., Camino-Lopez S., Crespo J., Carreras F., Leta R., et al. Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. J. Mol. Cell Cardiol. 2017;106:55–67. doi: 10.1016/j.yjmcc.2017.03.005. PubMed DOI

Gecys D., Tatarunas V., Veikutiene A., Lesauskaite V. New potential modulators of CYP4F2 enzyme activity in angina pectoris: Hsa-miR-24-3p and hsa-miR-34a-5p. Biomarkers. 2020;25:40–47. doi: 10.1080/1354750X.2019.1690580. PubMed DOI

Onrat S.T., Onrat E., Ercan Onay E., Yalım Z., Avşar A. The Genetic Determination of the Differentiation between Ischemic Dilated Cardiomyopathy and Idiopathic Dilated Cardiomyopathy. Genet. Test. Mol. Biomark. 2018;22:644–651. doi: 10.1089/gtmb.2018.0188. PubMed DOI

Tan H., Qi J., Fan B.Y., Zhang J., Su F.F., Wang H.T. MicroRNA-24-3p Attenuates Myocardial Ischemia/Reperfusion Injury by Suppressing RIPK1 Expression in Mice. Cell Physiol. Biochem. 2018;51:46–62. doi: 10.1159/000495161. PubMed DOI

Xiao X., Lu Z., Lin V., May A., Shaw D.H., Wang Z., Che B., Tran K., Du H., Shaw P.X. MicroRNA miR-24-3p Reduces Apoptosis and Regulates Keap1-Nrf2 Pathway in Mouse Cardiomyocytes Responding to Ischemia/Reperfusion Injury. Oxid. Med. Cell Longev. 2018;2018:7042105. doi: 10.1155/2018/7042105. PubMed DOI PMC

Gao J., Liu Q.G. The role of miR-26 in tumors and normal tissues. Oncol. Lett. 2011;2:1019–1023. doi: 10.3892/ol.2011.413. PubMed DOI PMC

Zheng L., Lin S., Lv C. MiR-26a-5p regulates cardiac fibroblasts collagen expression by targeting ULK1. Sci. Rep. 2018;8:2104. doi: 10.1038/s41598-018-20561-4. PubMed DOI PMC

Bye A., Røsjø H., Nauman J., Silva G.J., Follestad T., Omland T., Wisløff U. Circulating microRNAs predict future fatal myocardial infarction in healthy individuals - The HUNT study. J. Mol. Cell Cardiol. 2016;97:162–168. doi: 10.1016/j.yjmcc.2016.05.009. PubMed DOI

Hsu A., Chen S.J., Chang Y.S., Chen H.C., Chu P.H. Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. Biomed. Res. Int. 2014;2014:418628. doi: 10.1155/2014/418628. PubMed DOI PMC

Xing X., Guo S., Zhang G., Liu Y., Bi S., Wang X., Lu Q. miR-26a-5p protects against myocardial ischemia/reperfusion injury by regulating the PTEN/PI3K/AKT signaling pathway. Braz. J. Med. Biol. Res. 2020;53:e9106. doi: 10.1590/1414-431x20199106. PubMed DOI PMC

Chouvarine P., Geldner J., Giagnorio R., Legchenko E., Bertram H., Hansmann G. Trans-Right-Ventricle and Transpulmonary MicroRNA Gradients in Human Pulmonary Arterial Hypertension. Pediatr. Crit. Care Med. 2020;21:340–349. doi: 10.1097/PCC.0000000000002207. PubMed DOI

Garavelli S., Bruzzaniti S., Tagliabue E., Prattichizzo F., Di Silvestre D., Perna F., La Sala L., Ceriello A., Mozzillo E., Fattorusso V., et al. Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity. Int. J. Mol. Sci. 2020;21:477. doi: 10.3390/ijms21020477. PubMed DOI PMC

Ye Y., Hu Z., Lin Y., Zhang C., Perez-Polo J.R. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 2010;87:535–544. doi: 10.1093/cvr/cvq053. PubMed DOI

Moraes L.N., Fernandez G.J., Vechetti-Júnior I.J., Freire P.P., Souza R.W.A., Villacis R.A.R., Rogatto S.R., Reis P.P., Dal-Pai-Silva M., Carvalho R.F. Integration of miRNA and mRNA expression profiles reveals microRNA-regulated networks during muscle wasting in cardiac cachexia. Sci. Rep. 2017;7:6998. doi: 10.1038/s41598-017-07236-2. PubMed DOI PMC

Zhao Y., Yuan Y., Qiu C. Underexpression of CACNA1C Caused by Overexpression of microRNA-29a Underlies the Pathogenesis of Atrial Fibrillation. Med. Sci. Monit. 2016;22:2175–2181. doi: 10.12659/MSM.896191. PubMed DOI PMC

Zhang L., Zhang Y., Xue S., Ding H., Wang Y., Qi H., Wang Y., Zhu W., Li P. Clinical significance of circulating microRNAs as diagnostic biomarkers for coronary artery disease. J. Cell Mol. Med. 2020;24:1146–1150. doi: 10.1111/jcmm.14802. PubMed DOI PMC

Kong L., Zhu J., Han W., Jiang X., Xu M., Zhao Y., Dong Q., Pang Z., Guan Q., Gao L., et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol. 2011;48:61–69. doi: 10.1007/s00592-010-0226-0. PubMed DOI

Widlansky M.E., Jensen D.M., Wang J., Liu Y., Geurts A.M., Kriegel A.J., Liu P., Ying R., Zhang G., Casati M., et al. miR-29 contributes to normal endothelial function and can restore it in cardiometabolic disorders. EMBO Mol. Med. 2018;10:e8046. doi: 10.15252/emmm.201708046. PubMed DOI PMC

Bulent Vatan M., Kalaycı Yigin A., Akdemir R., Tarik Agac M., Akif Cakar M., Aksoy M., Tatli E., Kilic H., Gunduz H., Guzel D., et al. Altered Plasma MicroRNA Expression in Patients with Mitral Chordae Tendineae Rupture. J. Heart Valve Dis. 2016;25:580–588. PubMed

Gumus G., Giray D., Bobusoglu O., Tamer L., Karpuz D., Hallioglu O. MicroRNA values in children with rheumatic carditis: A preliminary study. Rheumatol. Int. 2018;38:1199–1205. doi: 10.1007/s00296-018-4069-2. PubMed DOI

Rogg E.M., Abplanalp W.T., Bischof C., John D., Schulz M.H., Krishnan J., Fischer A., Poluzzi C., Schaefer L., Bonauer A., et al. Analysis of Cell Type-Specific Effects of MicroRNA-92a Provides Novel Insights into Target Regulation and Mechanism of Action. Circulation. 2018;138:2545–2558. doi: 10.1161/CIRCULATIONAHA.118.034598. PubMed DOI

Marques F.Z., Vizi D., Khammy O., Mariani J.A., Kaye D.M. The transcardiac gradient of cardio-microRNAs in the failing heart. Eur. J. Heart Fail. 2016;18:1000–1008. doi: 10.1002/ejhf.517. PubMed DOI

Liu Y., Li Q., Hosen M.R., Zietzer A., Flender A., Levermann P., Schmitz T., Frühwald D., Goody P., Nickenig G., et al. Atherosclerotic Conditions Promote the Packaging of Functional MicroRNA-92a-3p Into Endothelial Microvesicles. Circ. Res. 2019;124:575–587. doi: 10.1161/CIRCRESAHA.118.314010. PubMed DOI

Wiese C.B., Zhong J., Xu Z.Q., Zhang Y., Ramirez Solano M.A., Zhu W., Linton M.F., Sheng Q., Kon V., Vickers K.C. Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis. Atherosclerosis. 2019;282:121–131. doi: 10.1016/j.atherosclerosis.2019.01.023. PubMed DOI PMC

Moncini S., Salvi A., Zuccotti P., Viero G., Quattrone A., Barlati S., De Petro G., Venturin M., Riva P. The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration. PLoS ONE. 2011;6:e20038. doi: 10.1371/journal.pone.0020038. PubMed DOI PMC

Huang L., Li L., Chen X., Zhang H., Shi Z. MiR-103a targeting Piezo1 is involved in acute myocardial infarction through regulating endothelium function. Cardiol. J. 2016;23:556–562. doi: 10.5603/CJ.a2016.0056. PubMed DOI

Deng B., Du J., Hu R., Wang A.P., Wu W.H., Hu C.P., Li Y.J., Li X.H. MicroRNA-103/107 is involved in hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by targeting HIF-1β. Life Sci. 2016;147:117–124. doi: 10.1016/j.lfs.2016.01.043. PubMed DOI

Trajkovski M., Hausser J., Soutschek J., Bhat B., Akin A., Zavolan M., Heim M.H., Stoffel M. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–653. doi: 10.1038/nature10112. PubMed DOI

Assmann T.S., Recamonde-Mendoza M., Puñales M., Tschiedel B., Canani L.H., Crispim D. MicroRNA expression profile in plasma from type 1 diabetic patients: Case-control study and bioinformatic analysis. Diabetes Res. Clin. Pract. 2018;141:35–46. doi: 10.1016/j.diabres.2018.03.044. PubMed DOI

Shaham L., Binder V., Gefen N., Borkhardt A., Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia. 2012;26:2011–2018. doi: 10.1038/leu.2012.90. PubMed DOI

Tiedt S., Prestel M., Malik R., Schieferdecker N., Duering M., Kautzky V., Stoycheva I., Böck J., Northoff B.H., Klein M., et al. RNA-Seq Identifies Circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as Potential Biomarkers for Acute Ischemic Stroke. Circ. Res. 2017;121:970–980. doi: 10.1161/CIRCRESAHA.117.311572. PubMed DOI

Jia K., Shi P., Han X., Chen T., Tang H., Wang J. Diagnostic value of miR-30d-5p and miR-125b-5p in acute myocardial infarction. Mol. Med. Rep. 2016;14:184–194. doi: 10.3892/mmr.2016.5246. PubMed DOI PMC

Bayoumi A.S., Park K.M., Wang Y., Teoh J.P., Aonuma T., Tang Y., Su H., Weintraub N.L., Kim I.M. A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes. J. Mol. Cell Cardiol. 2018;114:72–82. doi: 10.1016/j.yjmcc.2017.11.003. PubMed DOI PMC

Satake E., Pezzolesi M.G., Md Dom Z.I., Smiles A.M., Niewczas M.A., Krolewski A.S. Circulating miRNA Profiles Associated with Hyperglycemia in Patients with Type 1 Diabetes. Diabetes. 2018;67:1013–1023. doi: 10.2337/db17-1207. PubMed DOI PMC

Samandari N., Mirza A.H., Kaur S., Hougaard P., Nielsen L.B., Fredheim S., Mortensen H.B., Pociot F. Influence of Disease Duration on Circulating Levels of miRNAs in Children and Adolescents with New Onset Type 1 Diabetes. Noncoding RNA. 2018;4:35. doi: 10.3390/ncrna4040035. PubMed DOI PMC

Yu C.Y., Yang C.Y., Rui Z.L. MicroRNA-125b-5p improves pancreatic β-cell function through inhibiting JNK signaling pathway by targeting DACT1 in mice with type 2 diabetes mellitus. Life Sci. 2019;224:67–75. doi: 10.1016/j.lfs.2019.01.031. PubMed DOI

Wu X.J., Zhao Z.F., Kang X.J., Wang H.J., Zhao J., Pu X.M. MicroRNA-126-3p suppresses cell proliferation by targeting PIK3R2 in Kaposi’s sarcoma cells. Oncotarget. 2016;7:36614–36621. doi: 10.18632/oncotarget.9311. PubMed DOI PMC

Matsha T.E., Kengne A.P., Hector S., Mbu D.L., Yako Y.Y., Erasmus R.T. MicroRNA profiling and their pathways in South African individuals with prediabetes and newly diagnosed type 2 diabetes mellitus. Oncotarget. 2018;9:30485–30498. doi: 10.18632/oncotarget.25271. PubMed DOI PMC

Lan X., Wu L., Wu N., Chen Q., Li Y., Du X., Wei C., Feng L., Li Y., Osoro E.K., et al. Long Noncoding RNA lnc-HC Regulates PPARγ-Mediated Hepatic Lipid Metabolism through miR-130b-3p. Mol. Ther. Nucleic Acids. 2019;18:954–965. doi: 10.1016/j.omtn.2019.10.018. PubMed DOI PMC

Zhang J., Jazii F.R., Haghighi M.M., Alvares D., Liu L., Khosraviani N., Adeli K. miR-130b is a potent stimulator of hepatic very-low-density lipoprotein assembly and secretion via marked induction of microsomal triglyceride transfer protein. Am. J. Physiol. Endocrinol. Metab. 2020;318:E262–E275. doi: 10.1152/ajpendo.00276.2019. PubMed DOI

Li P., Zhang Q., Wu X., Yang X., Zhang Y., Li Y., Jiang F. Circulating microRNAs serve as novel biological markers for intracranial aneurysms. J. Am. Heart Assoc. 2014;3:e000972. doi: 10.1161/JAHA.114.000972. PubMed DOI PMC

Tian C., Li Z., Yang Z., Huang Q., Liu J., Hong B. Plasma MicroRNA-16 Is a Biomarker for Diagnosis, Stratification, and Prognosis of Hyperacute Cerebral Infarction. PLoS ONE. 2016;11:e0166688. doi: 10.1371/journal.pone.0166688. PubMed DOI PMC

Prabu P., Rome S., Sathishkumar C., Aravind S., Mahalingam B., Shanthirani C.S., Gastebois C., Villard A., Mohan V., Balasubramanyam M. Circulating MiRNAs of ‘Asian Indian Phenotype’ Identified in Subjects with Impaired Glucose Tolerance and Patients with Type 2 Diabetes. PLoS ONE. 2015;10:e0128372. doi: 10.1371/journal.pone.0128372. PubMed DOI PMC

Feng T., Li K., Zheng P., Wang Y., Lv Y., Shen L., Chen Y., Xue Z., Li B., Jin L., et al. Weighted Gene Coexpression Network Analysis Identified MicroRNA Coexpression Modules and Related Pathways in Type 2 Diabetes Mellitus. Oxid. Med. Cell Longev. 2019;2019:9567641. doi: 10.1155/2019/9567641. PubMed DOI PMC

Liang H.W., Yang X., Wen D.Y., Gao L., Zhang X.Y., Ye Z.H., Luo J., Li Z.Y., He Y., Pang Y.Y., et al. Utility of miR 133a 3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta analysis and bioinformatics. Mol. Med. Rep. 2018;17:1469–1484. doi: 10.3892/mmr.2017.8040. PubMed DOI PMC

Van Rooij E., Olson E.N. MicroRNAs: Powerful new regulators of heart disease and provocative therapeutic targets. J. Clin. Investig. 2007;117:2369–2376. doi: 10.1172/JCI33099. PubMed DOI PMC

Wang J., Xu R., Lin F., Zhang S., Zhang G., Hu S., Zheng Z. MicroRNA: Novel regulators involved in the remodeling and reverse remodeling of the heart. Cardiology. 2009;113:81–88. doi: 10.1159/000172616. PubMed DOI

Kukreja R.C., Yin C., Salloum F.N. MicroRNAs: New players in cardiac injury and protection. Mol. Pharmacol. 2011;80:558–564. doi: 10.1124/mol.111.073528. PubMed DOI PMC

Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., Herias V., van Leeuwen R.E., Schellings M.W., Barenbrug P., et al. miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 2009;104:170–178. doi: 10.1161/CIRCRESAHA.108.182535. PubMed DOI

Liu W., Ling S., Sun W., Liu T., Li Y., Zhong G., Zhao D., Zhang P., Song J., Jin X., et al. Circulating microRNAs correlated with the level of coronary artery calcification in symptomatic patients. Sci. Rep. 2015;5:16099. doi: 10.1038/srep16099. PubMed DOI PMC

Jiang Y., Zhang M., He H., Chen J., Zeng H., Li J., Duan R. MicroRNA/mRNA profiling and regulatory network of intracranial aneurysm. BMC Med. Genom. 2013;6:36. doi: 10.1186/1755-8794-6-36. PubMed DOI PMC

Liu H., Xiong W., Liu F., Lin F., He J., Liu C., Lin Y., Dong S. Significant role and mechanism of microRNA-143-3p/KLLN axis in the development of coronary heart disease. Am. J. Transl. Res. 2019;11:3610–3619. PubMed PMC

Li C., Li J., Xue K., Zhang J., Wang C., Zhang Q., Chen X., Gao C., Yu X., Sun L. MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 after myocardial infarction. J. Mol. Cell Cardiol. 2019;129:281–292. doi: 10.1016/j.yjmcc.2019.03.005. PubMed DOI

Yu B., Zhao Y., Zhang H., Xie D., Nie W., Shi K. Inhibition of microRNA-143-3p attenuates myocardial hypertrophy by inhibiting inflammatory response. Cell Biol. Int. 2018;42:1584–1593. doi: 10.1002/cbin.11053. PubMed DOI

Jiao M., You H.Z., Yang X.Y., Yuan H., Li Y.L., Liu W.X., Jin M., Du J. Circulating microRNA signature for the diagnosis of childhood dilated cardiomyopathy. Sci. Rep. 2018;8:724. doi: 10.1038/s41598-017-19138-4. PubMed DOI PMC

Deng L., Blanco F.J., Stevens H., Lu R., Caudrillier A., McBride M., McClure J.D., Grant J., Thomas M., Frid M., et al. MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension. Circ. Res. 2015;117:870–883. doi: 10.1161/CIRCRESAHA.115.306806. PubMed DOI PMC

Shi L., Tian C., Sun L., Cao F., Meng Z. The lncRNA TUG1/miR-145-5p/FGF10 regulates proliferation and migration in VSMCs of hypertension. Biochem. Biophys. Res. Commun. 2018;501:688–695. doi: 10.1016/j.bbrc.2018.05.049. PubMed DOI

Yang X., Niu X., Xiao Y., Lin K., Chen X. MiRNA expression profiles in healthy OSAHS and OSAHS with arterial hypertension: Potential diagnostic and early warning markers. Respir. Res. 2018;19:194. doi: 10.1186/s12931-018-0894-9. PubMed DOI PMC

Toro R., Blasco-Turrión S., Morales-Ponce F.J., Gonzalez P., Martínez-Camblor P., López-Granados A., Brugada R., Campuzano O., Pérez-Serra A., Rosa Longobardo F., et al. Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy. J. Mol. Med. 2018;96:845–856. doi: 10.1007/s00109-018-1666-1. PubMed DOI

Yuan M., Zhang L., You F., Zhou J., Ma Y., Yang F., Tao L. MiR-145-5p regulates hypoxia-induced inflammatory response and apoptosis in cardiomyocytes by targeting CD40. Mol. Cell Biochem. 2017;431:123–131. doi: 10.1007/s11010-017-2982-4. PubMed DOI

Wu G., Tan J., Li J., Sun X., Du L., Tao S. miRNA-145-5p induces apoptosis after ischemia-reperfusion by targeting dual specificity phosphatase 6. J. Cell Physiol. 2019;234:16281–16289. doi: 10.1002/jcp.28291. PubMed DOI

Xie X., Peng L., Zhu J., Zhou Y., Li L., Chen Y., Yu S., Zhao Y. miR-145-5p/Nurr1/TNF-α Signaling-Induced Microglia Activation Regulates Neuron Injury of Acute Cerebral Ischemic/Reperfusion in Rats. Front. Mol. Neurosci. 2017;10:383. doi: 10.3389/fnmol.2017.00383. PubMed DOI PMC

Nunez Lopez Y.O., Retnakaran R., Zinman B., Pratley R.E., Seyhan A.A. Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. Mol. Metab. 2019;20:63–78. doi: 10.1016/j.molmet.2018.11.003. PubMed DOI PMC

Zhang J., Cui C., Xu H. Downregulation of miR-145-5p elevates retinal ganglion cell survival to delay diabetic retinopathy progress by targeting FGF5. Biosci. Biotechnol. Biochem. 2019;83:1655–1662. doi: 10.1080/09168451.2019.1630251. PubMed DOI

Mona Zamanian A., Rezaei-Tavirani M., Rezaei-Tavirani M., Robati R.M. Gestational Diabetes Mellitus Regulatory Network Identifies hsa-miR-145-5p and hsa-miR-875-5p as Potential Biomarkers. Int. J. Endocrinol. Metab. 2019;17:e86640. PubMed PMC

Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA. 2006;103:12481–12486. doi: 10.1073/pnas.0605298103. PubMed DOI PMC

Paterson M.R., Kriegel A.J. MiR-146a/b: A family with shared seeds and different roots. Physiol. Genom. 2017;49:243–252. doi: 10.1152/physiolgenomics.00133.2016. PubMed DOI PMC

Zhang X., Ye Z.H., Liang H.W., Ren F.H., Li P., Dang Y.W., Chen G. Down-regulation of miR-146a-5p and its potential targets in hepatocellular carcinoma validated by a TCGA- and GEO-based study. FEBS Open Bio. 2017;7:504–521. doi: 10.1002/2211-5463.12198. PubMed DOI PMC

Wang X., Ha T., Liu L., Zou J., Zhang X., Kalbfleisch J., Gao X., Williams D., Li C. Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc. Res. 2013;97:432–442. doi: 10.1093/cvr/cvs356. PubMed DOI PMC

Quan X., Ji Y., Zhang C., Guo X., Zhang Y., Jia S., Ma W., Fan Y., Wang C. Circulating MiR-146a May be a Potential Biomarker of Coronary Heart Disease in Patients with Subclinical Hypothyroidism. Cell Physiol. Biochem. 2018;45:226–236. doi: 10.1159/000486769. PubMed DOI

Li S.H., Chen L., Pang X.M., Su S.Y., Zhou X., Chen C.Y., Huang L.G., Li J.P., Liu J.L. Decreased miR-146a expression in acute ischemic stroke directly targets the Fbxl10 mRNA and is involved in modulating apoptosis. Neurochem. Int. 2017;107:156–167. doi: 10.1016/j.neuint.2017.01.011. PubMed DOI

Barberio M.D., Kasselman L.J., Playford M.P., Epstein S.B., Renna H.A., Goldberg M., DeLeon J., Voloshyna I., Barlev A., Salama M., et al. Cholesterol efflux alterations in adolescent obesity: Role of adipose-derived extracellular vesical microRNAs. J. Transl. Med. 2019;17:232. doi: 10.1186/s12967-019-1980-6. PubMed DOI PMC

Gaudet A.D., Fonken L.K., Gushchina L.V., Aubrecht T.G., Maurya S.K., Periasamy M., Nelson R.J., Popovich P.G. miR-155 Deletion in Female Mice Prevents Diet-Induced Obesity. Sci. Rep. 2016;6:22862. doi: 10.1038/srep22862. PubMed DOI PMC

Chen L., Zheng S.Y., Yang C.Q., Ma B.M., Jiang D. MiR-155-5p inhibits the proliferation and migration of VSMCs and HUVECs in atherosclerosis by targeting AKT1. Eur. Rev. Med. Pharmacol. Sci. 2019;23:2223–2233. PubMed

Zhu M., Wei Y., Geißler C., Abschlag K., Corbalán Campos J., Hristov M., Möllmann J., Lehrke M., Karshovska E., Schober A. Hyperlipidemia-Induced MicroRNA-155-5p Improves β-Cell Function by Targeting Mafb. Diabetes. 2017;66:3072–3084. doi: 10.2337/db17-0313. PubMed DOI

Li S., Lee C., Song J., Lu C., Liu J., Cui Y., Liang H., Cao C., Zhang F., Chen H. Circulating microRNAs as potential biomarkers for coronary plaque rupture. Oncotarget. 2017;8:48145–48156. doi: 10.18632/oncotarget.18308. PubMed DOI PMC

Mukai N., Nakayama Y., Murakami S., Tanahashi T., Sessler D.I., Ishii S., Ogawa S., Tokuhira N., Mizobe T., Sawa T., et al. Potential contribution of erythrocyte microRNA to secondary erythrocytosis and thrombocytopenia in congenital heart disease. Pediatr. Res. 2018;83:866–873. doi: 10.1038/pr.2017.327. PubMed DOI

Klimczak D., Kuch M., Pilecki T., Żochowska D., Wirkowska A., Pączek L. Plasma microRNA-155-5p is increased among patients with chronic kidney disease and nocturnal hypertension. J. Am. Soc. Hypertens. 2017;11:831–841.e4. doi: 10.1016/j.jash.2017.10.008. PubMed DOI

Wang M., Sun L., Ding W., Cai S., Zhao Q. Ablation alleviates atrial fibrillation by regulating the signaling pathways of endothelial nitric oxide synthase/nitric oxide via miR-155-5p and miR-24-3p. J. Cell Biochem. 2019;120:4451–4462. doi: 10.1002/jcb.27733. PubMed DOI

Sun X., Sit A., Feinberg M.W. Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc. Med. 2014;24:105–112. doi: 10.1016/j.tcm.2013.09.002. PubMed DOI PMC

Hulsmans M., Sinnaeve P., Van der Schueren B., Mathieu C., Janssens S., Holvoet P. Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. J. Clin. Endocrinol. Metab. 2012;97:E1213–E1218. doi: 10.1210/jc.2012-1008. PubMed DOI

Du X., Yang Y., Xu C., Peng Z., Zhang M., Lei L., Gao W., Dong Y., Shi Z., Sun X., et al. Upregulation of miR-181a impairs hepatic glucose and lipid homeostasis. Oncotarget. 2017;8:91362–91378. doi: 10.18632/oncotarget.20523. PubMed DOI PMC

Wu J., Fan C.L., Ma L.J., Liu T., Wang C., Song J.X., Lv Q.S., Pan H., Zhang C.N., Wang J.J. Distinctive expression signatures of serum microRNAs in ischaemic stroke and transient ischaemic attack patients. Thromb. Haemost. 2017;117:992–1001. PubMed

Zhu J., Yao K., Wang Q., Guo J., Shi H., Ma L., Liu H., Gao W., Zou Y., Ge J. Circulating miR-181a as a Potential Novel Biomarker for Diagnosis of Acute Myocardial Infarction. Cell Physiol. Biochem. 2016;40:1591–1602. doi: 10.1159/000453209. PubMed DOI

Nabih E.S., Andrawes N.G. The Association Between Circulating Levels of miRNA-181a and Pancreatic Beta Cells Dysfunction via SMAD7 in Type 1 Diabetic Children and Adolescents. J. Clin. Lab. Anal. 2016;30:727–731. doi: 10.1002/jcla.21928. PubMed DOI PMC

He J.F., Luo Y.M., Wan X.H., Jiang D. Biogenesis of MiRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J. Biochem. Mol. Toxicol. 2011;25:404–408. doi: 10.1002/jbt.20396. PubMed DOI

Van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., Richardson J.A., Olson E.N. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. USA. 2006;103:18255–18260. doi: 10.1073/pnas.0608791103. PubMed DOI PMC

You X.Y., Huang J.H., Liu B., Liu S.J., Zhong Y., Liu S.M. HMGA1 is a new target of miR-195 involving isoprenaline-induced cardiomyocyte hypertrophy. Biochemistry. 2014;79:538–544. doi: 10.1134/S0006297914060078. PubMed DOI

Zampetaki A., Attia R., Mayr U., Gomes R.S., Phinikaridou A., Yin X., Langley S.R., Willeit P., Lu R., Fanshawe B., et al. Role of miR-195 in aortic aneurysmal disease. Circ. Res. 2014;115:857–866. doi: 10.1161/CIRCRESAHA.115.304361. PubMed DOI

Du J., Zheng R., Xiao F., Zhang S., He K., Zhang J., Shao Y. Downregulated MicroRNA-195 in the Bicuspid Aortic Valve Promotes Calcification of Valve Interstitial Cells via Targeting SMAD7. Cell Physiol. Biochem. 2017;44:884–896. doi: 10.1159/000485356. PubMed DOI

Collares C.V., Evangelista A.F., Xavier D.J., Rassi D.M., Arns T., Foss-Freitas M.C., Foss M.C., Puthier D., Sakamoto-Hojo E.T., Passos G.A., et al. Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients. BMC Res. Notes. 2013;6:491. doi: 10.1186/1756-0500-6-491. PubMed DOI PMC

Massaro J.D., Polli C.D., Costa E., Silva M., Alves C.C., Passos G.A., Sakamoto-Hojo E.T., Rodrigues de Holanda Miranda W., Bispo Cezar N.J., Rassi D.M., et al. Post-transcriptional markers associated with clinical complications in Type 1 and Type 2 diabetes mellitus. Mol. Cell Endocrinol. 2019;490:1–14. doi: 10.1016/j.mce.2019.03.008. PubMed DOI

Li M., Luan L., Liu Q., Liu Y., Lan X., Li Z., Liu W. MiRNA-199a-5p Protects Against Cerebral Ischemic Injury by Down-Regulating DDR1 in Rats. World Neurosurg. 2019;131:e486–e494. doi: 10.1016/j.wneu.2019.07.203. PubMed DOI

Yan M., Yang S., Meng F., Zhao Z., Tian Z., Yang P. MicroRNA 199a-5p induces apoptosis by targeting JunB. Sci. Rep. 2018;8:6699. doi: 10.1038/s41598-018-24932-9. PubMed DOI PMC

Lynch S.M., Ward M., McNulty H., Angel C.Z., Horigan G., Strain J.J., Purvis J., Tackett M., McKenna D.J. Serum levels of miR-199a-5p correlates with blood pressure in premature cardiovascular disease patients homozygous for the MTHFR 677C > T polymorphism. Genom. 2020;112:669–676. doi: 10.1016/j.ygeno.2019.04.019. PubMed DOI

Tian X., Yu C., Shi L., Li D., Chen X., Xia D., Zhou J., Xu W., Ma C., Gu L., et al. MicroRNA-199a-5p aggravates primary hypertension by damaging vascular endothelial cells through inhibition of autophagy and promotion of apoptosis. Exp. Ther. Med. 2018;16:595–602. doi: 10.3892/etm.2018.6252. PubMed DOI PMC

Zhou Y., Pang B., Xiao Y., Zhou S., He B., Zhang F., Liu W., Peng H., Li P. The protective microRNA-199a-5p-mediated unfolded protein response in hypoxic cardiomyocytes is regulated by STAT3 pathway. J. Physiol. Biochem. 2019;75:73–81. doi: 10.1007/s13105-018-0657-6. PubMed DOI

Liu Y., Liu G., Zhang H., Wang J. MiRNA-199a-5p influences pulmonary artery hypertension via downregulating Smad3. Biochem. Biophys. Res. Commun. 2016;473:859–866. doi: 10.1016/j.bbrc.2016.03.140. PubMed DOI

Wang J., Yu G. A Systems Biology Approach to Characterize Biomarkers for Blood Stasis Syndrome of Unstable Angina Patients by Integrating MicroRNA and Messenger RNA Expression Profiling. Evid. Based Complement. Altern. Med. 2013;2013:510208. doi: 10.1155/2013/510208. PubMed DOI PMC

Yu L., Gu T., Shi E., Wang Y., Fang Q., Wang C. Dysregulation of renal microRNA expression after deep hypothermic circulatory arrest in rats. Eur J. Cardiothorac. Surg. 2016;49:1725–1731. doi: 10.1093/ejcts/ezv460. PubMed DOI

Hirt M.N., Werner T., Indenbirken D., Alawi M., Demin P., Kunze A.C., Stenzig J., Starbatty J., Hansen A., Fiedler J., et al. Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. J. Mol. Cell Cardiol. 2015;81:1–9. doi: 10.1016/j.yjmcc.2015.01.008. PubMed DOI

Aguado-Fraile E., Ramos E., Conde E., Rodríguez M., Martín-Gómez L., Lietor A., Candela Á., Ponte B., Liaño F., García-Bermejo M.L. A Pilot Study Identifying a Set of microRNAs As Precise Diagnostic Biomarkers of Acute Kidney Injury. PLoS ONE. 2015;10:e0127175. doi: 10.1371/journal.pone.0127175. PubMed DOI PMC

Ma H., Chen P., Sang C., Huang D., Geng Q., Wang L. Modulation of apoptosis-related microRNAs following myocardial infarction in fat-1 transgenic mice vs wild-type mice. J. Cell Mol. Med. 2018;22:5698–5707. doi: 10.1111/jcmm.13846. PubMed DOI PMC

Qiao X.R., Wang L., Liu M., Tian Y., Chen T. MiR-210-3p attenuates lipid accumulation and inflammation in atherosclerosis by repressing IGF2. Biosci. Biotechnol. Biochem. 2020;84:321–329. doi: 10.1080/09168451.2019.1685370. PubMed DOI

Derda A.A., Pfanne A., Bwangär C., Schimmel K., Kennel P.J., Xiao K., Schulze P.C., Bauersachs J., Thum T. Blood-based microRNA profiling in patients with cardiac amyloidosis. PLoS ONE. 2018;13:e0204235. doi: 10.1371/journal.pone.0204235. PubMed DOI PMC

Verjans R., Peters T., Beaumont F.J., van Leeuwen R., van Herwaarden T., Verhesen W., Munts C., Bijnen M., Henkens M., Diez J., et al. MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. Hypertension. 2018;71:280–288. doi: 10.1161/HYPERTENSIONAHA.117.10094. PubMed DOI

Zhuang X., Li R., Maimaitijiang A., Liu R., Yan F., Hu H., Gao X., Shi H. miR-221-3p inhibits oxidized low-density lipoprotein induced oxidative stress and apoptosis via targeting a disintegrin and metalloprotease-22. J. Cell Biochem. 2019;120:6304–6314. doi: 10.1002/jcb.27917. PubMed DOI

Pereira-da-Silva T., Coutinho Cruz M., Carrusca C., Cruz Ferreira R., Napoleão P., Mota Carmo M. Circulating microRNA profiles in different arterial territories of stable atherosclerotic disease: A systematic review. Am. J. Cardiovasc. Dis. 2018;8:1–13. PubMed PMC

Coffey S., Williams M.J., Phillips L.V., Galvin I.F., Bunton R.W., Jones G.T. Integrated microRNA and messenger RNA analysis in aortic stenosis. Sci. Rep. 2016;6:36904. doi: 10.1038/srep36904. PubMed DOI PMC

Coskunpinar E., Cakmak H.A., Kalkan A.K., Tiryakioglu N.O., Erturk M., Ongen Z. Circulating miR-221-3p as a novel marker for early prediction of acute myocardial infarction. Gene. 2016;591:90–96. doi: 10.1016/j.gene.2016.06.059. PubMed DOI

Sørensen S.S., Nygaard A.B., Nielsen M.Y., Jensen K., Christensen T. miRNA expression profiles in cerebrospinal fluid and blood of patients with acute ischemic stroke. Transl. Stroke Res. 2014;5:711–718. doi: 10.1007/s12975-014-0364-8. PubMed DOI

Gusar V.A., Timofeeva A.V., Zhanin I.S., Shram S.I., Pinelis V.G. Estimation of Time-Dependent microRNA Expression Patterns in Brain Tissue, Leukocytes, and Blood Plasma of Rats under Photochemically Induced Focal Cerebral Ischemia. Mol. Biol. 2017;51:683–695. doi: 10.1134/S0026893317040100. PubMed DOI

Nie X., Chen Y., Tan J., Dai Y., Mao W., Qin G., Ye S., Sun J., Yang Z., Chen J. MicroRNA-221-3p promotes pulmonary artery smooth muscle cells proliferation by targeting AXIN2 during pulmonary arterial hypertension. Vascul. Pharmacol. 2019;116:24–35. doi: 10.1016/j.vph.2017.07.002. PubMed DOI

Villard A., Marchand L., Thivolet C., Rome S. Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis. J. Mol. Biomark. Diagn. 2015;6:251. doi: 10.4172/2155-9929.1000251. PubMed DOI PMC

Wang L., Xu L., Xu M., Liu G., Xing J., Sun C., Ding H. Obesity-Associated MiR-342-3p Promotes Adipogenesis of Mesenchymal Stem Cells by Suppressing CtBP2 and Releasing C/EBPα from CtBP2 Binding. Cell Physiol. Biochem. 2015;35:2285–2298. doi: 10.1159/000374032. PubMed DOI

Hezova R., Slaby O., Faltejskova P., Mikulkova Z., Buresova I., Raja K.R., Hodek J., Ovesna J., Michalek J. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol. 2010;260:70–74. doi: 10.1016/j.cellimm.2009.10.012. PubMed DOI

Eissa S., Matboli M., Bekhet M.M. Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis. Biomed. Pharmacother. 2016;83:92–99. doi: 10.1016/j.biopha.2016.06.018. PubMed DOI

Cheng S., Cui Y., Fan L., Mu X., Hua Y. T2DM inhibition of endothelial miR-342-3p facilitates angiogenic dysfunction via repression of FGF11 signaling. Biochem. Biophys. Res. Commun. 2018;503:71–78. doi: 10.1016/j.bbrc.2018.05.179. PubMed DOI

Khalyfa A., Kheirandish-Gozal L., Bhattacharjee R., Khalyfa A.A., Gozal D. Circulating microRNAs as Potential Biomarkers of Endothelial Dysfunction in Obese Children. Chest. 2016;149:786–800. doi: 10.1378/chest.15-0799. PubMed DOI PMC

Hoekstra M. MicroRNA-499-5p: A therapeutic target in the context of cardiovascular disease. Ann. Transl. Med. 2016;4:539. doi: 10.21037/atm.2016.11.61. PubMed DOI PMC

Zhao L., Wang B., Zhang W., Sun L. Effect of miR-499a-5p on damage of cardiomyocyte induced by hypoxia-reoxygenation via downregulating CD38 protein. J. Cell Biochem. 2020;121:996–1004. doi: 10.1002/jcb.29334. PubMed DOI

Neshati V., Mollazadeh S., Fazly Bazzaz B.S., de Vries A.A.F., Mojarrad M., Naderi-Meshkin H., Neshati Z., Mirahmadi M., Kerachian M.A. MicroRNA-499a-5p Promotes Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells to Cardiomyocytes. Appl. Biochem. Biotechnol. 2018;186:245–255. doi: 10.1007/s12010-018-2734-2. PubMed DOI

Boštjančič E., Zidar N., Glavač D. MicroRNAs and cardiac sarcoplasmic reticulum calcium ATPase-2 in human myocardial infarction: Expression and bioinformatic analysis. BMC Genom. 2012;13:552. doi: 10.1186/1471-2164-13-552. PubMed DOI PMC

Salinas J., Lin H., Aparico H.J., Huan T., Liu C., Rong J., Beiser A., Himali J.J., Freedman J.E., Larson M.G., et al. Whole blood microRNA expression associated with stroke: Results from the Framingham Heart Study. PLoS ONE. 2019;14:e0219261. doi: 10.1371/journal.pone.0219261. PubMed DOI PMC

Baldeón Rojas L., Weigelt K., de Wit H., Ozcan B., van Oudenaren A., Sempértegui F., Sijbrands E., Grosse L., Van Zonneveld A.J., Drexhage H.A., et al. Study on inflammation-related genes and microRNAs, with special emphasis on the vascular repair factor HGF and miR-574-3p, in monocytes and serum of patients with T2D. Diabetol. Metab. Syndr. 2016;8:6. doi: 10.1186/s13098-015-0113-5. PubMed DOI PMC

Houshmand-Oeregaard A., Schrölkamp M., Kelstrup L., Hansen N.S., Hjort L., Thuesen A.C.B., Broholm C., Mathiesen E.R., Clausen T.D., Vaag A., et al. Increased Expression of microRNA-15a and microRNA-15b in Skeletal Muscle from Adult Offspring of Women with Diabetes in Pregnancy. Hum. Mol. Genet. 2018;27:1763–1771. doi: 10.1093/hmg/ddy085. PubMed DOI

International Association of Diabetes and Pregnancy Study Groups Consensus Panel. Metzger B.E., Gabbe S.G., Persson B., Buchanan T.A., Catalano P.A., Damm P., Dyer A.R., Leiva A.D., Hod M., et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676–682. doi: 10.2337/dc10-0719. PubMed DOI PMC

American Diabetes Association Diagnosis and classification of diabetes mellitus (Position Statement) Diabetes Care. 2009;32:S62–S67. doi: 10.2337/dc09-S062. PubMed DOI PMC

Metzger B.E., Coustan D.R. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998;21:B161–B167. PubMed

Hromadnikova I., Kotlabova K., Dvorakova L., Krofta L., Sirc J. Postnatal Expression Profile of microRNAs Associated with Cardiovascular and Cerebrovascular Diseases in Children at the Age of 3 to 11 Years in Relation to Previous Occurrence of Pregnancy-Related Complications. Int. J. Mol. Sci. 2019;20:654. doi: 10.3390/ijms20030654. PubMed DOI PMC

National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–576. doi: 10.1542/peds.114.2.S2.555. PubMed DOI

Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

Vandesompele J., de Preter K., Pattyn F., Poppe B., Van Roy N., de Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:research0034. doi: 10.1186/gb-2002-3-7-research0034. PubMed DOI PMC

Shapiro S.S., Wilk M.B. An Analysis of Variance Test for Normality (Complete Samples) Biometrika. 1965;52:591–611. doi: 10.1093/biomet/52.3-4.591. DOI

Dweep H., Sticht C., Pandey P., Gretz N. miRWalk—database: Prediction of possible miRNA binding sites by “walking” the genes of three genomes. J. Biomed. Inform. 2011;44:839–847. doi: 10.1016/j.jbi.2011.05.002. PubMed DOI

Hromadnikova I. Postnatální Epigenetický Profil Kardiovaskulárních MikroRNA U Dětí Narozených Z Komplikovaných Gravidit-Nové Biomarkery Kardiovaskulárního Rizika. 308102. CZ Patent. 2018 Oct 31; Issued 20 November 2019. Industrial Property Office, Czech Republic.

Hromadnikova I. A Method of Predicting a Risk of Cardiovascular Disease for a Child Born from a Complicated Pregnancy. PCT International Application No. PCT/CZ2019/050050. 2019 Oct 30; Industrial Property Office, Czech Republic.

Rivera R.M., Bennett L.B. Epigenetics in Humans: An Overview. Curr. Opin. Endocrinol. Diabetes Obes. 2010;17:493–499. doi: 10.1097/MED.0b013e3283404f4b. PubMed DOI

Saetrom P., Snøve O., Jr., Rossi J.J. Epigenetics and microRNAs. Pediatr. Res. 2007;61:17R–23R. doi: 10.1203/pdr.0b013e318045760e. PubMed DOI

Tost J. Epigenetics. Caister Academic Press; Norfolk, UK: 2008. pp. 1–404.

Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 2002;3:662–673. doi: 10.1038/nrg887. PubMed DOI

Sinkkonen L., Hugenschmidt T., Berninger P., Gaidatzis D., Mohn F., Artus-Revel C.G., Zavolan M., Svoboda P., Filipowicz W. MicroRNAs Control De Novo DNA Methylation Through Regulation of Transcriptional Repressors in Mouse Embryonic Stem Cells. Nat. Struct. Mol. Biol. 2008;15:259–267. doi: 10.1038/nsmb.1391. PubMed DOI

Ma J., Flemr M., Stein P., Berninger P., Malik R., Zavolan M., Svoboda P., Schultz R.M. MicroRNA Activity Is Suppressed in Mouse Oocytes. Curr. Biol. 2010;20:265–270. doi: 10.1016/j.cub.2009.12.042. PubMed DOI PMC

Suh N., Baehner L., Moltzahn F., Melton C., Shenoy A., Chen J., Blelloch R. MicroRNA Function Is Globally Suppressed in Mouse Oocytes and Early Embryos. Curr. Biol. 2010;20:271–277. doi: 10.1016/j.cub.2009.12.044. PubMed DOI PMC

Gu Y., Sun J., Groome L.J., Wang Y. Differential miRNA expression profiles between the first and third trimester human placentas. Am. J. Physiol. Endocrinol. Metab. 2013;304:E836–E843. doi: 10.1152/ajpendo.00660.2012. PubMed DOI PMC

Maccani M.A., Padbury J.F., Lester B.M., Knopik V.S., Marsit C.J. Placental miRNA expression profiles are associated with measures of infant neurobehavioral outcomes. Pediatr. Res. 2013;74:272–278. doi: 10.1038/pr.2013.102. PubMed DOI PMC

Soni K., Choudhary A., Patowary A., Singh A.R., Bhatia S., Sivasubbu S., Chandrasekaran S., Pillai B. miR-34 Is Maternally Inherited in Drosophila Melanogaster and Danio Rerio. Nucleic Acids Res. 2013;41:4470–4480. doi: 10.1093/nar/gkt139. PubMed DOI PMC

Babenko O., Kovalchuka I., Metz G.A. Epigenetic programming of neurodegenerative diseases by an adverse environment. Brain Res. 2015;1444:96–111. doi: 10.1016/j.brainres.2012.01.038. PubMed DOI

Rodgers A.B., Morgan C.P., Leu N.A., Bale T.L. Transgenerational epigenetic programming via sperm microRNA recapitulates effects of paternal stress. Proc. Natl. Acad. Sci. USA. 2015;112:13699–13704. doi: 10.1073/pnas.1508347112. PubMed DOI PMC

Fraser R., Lin C.J. Epigenetic reprogramming of the zygote in mice and men: On your marks, get set, go! Reproduction. 2016;152:R211–R222. doi: 10.1530/REP-16-0376. PubMed DOI PMC

Pang T.Y.C., Short A.K., Bredy T.W., Hannan A.J. Transgenerational paternal transmission of acquired traits: Stress-induced modification of the sperm regulatory transcriptome and offspring phenotypes. Curr. Opin. Behav. Sci. 2017;14:140–147. doi: 10.1016/j.cobeha.2017.02.007. PubMed DOI PMC

Yeshurun S., Hannan A.J. Transgenerational epigenetic influences of paternal environmental exposures on brain function and predisposition to psychiatric disorders. Mol. Psychiatry. 2019;24:536–548. doi: 10.1038/s41380-018-0039-z. PubMed DOI

Lacal I., Ventura R. Epigenetic Inheritance: Concepts, Mechanisms and Perspectives. Front. Mol. Neurosci. 2018;11:292. doi: 10.3389/fnmol.2018.00292. PubMed DOI PMC

Mathers J.C., Strathdee G., Relton C.L. Induction of epigenetic alterations by dietary and other environmental factors. Adv. Genet. 2010;71:3–39. PubMed

Christensen B.C., Marsit C.J. Epigenomics in environmental health. Front. Genet. 2011;2:84. doi: 10.3389/fgene.2011.00084. PubMed DOI PMC

Talikka M., Sierro N., Ivanov N.V., Chaudhary N., Peck M.J., Hoeng J., Coggins C.R.E., Peitsch C.M. Genomic Impact of Cigarette Smoke, With Application to Three Smoking-Related Diseases. Crit. Rev. Toxicol. 2012;42:877–889. doi: 10.3109/10408444.2012.725244. PubMed DOI PMC

Cabib S., Puglisi-Allegra S. The mesoaccumbens dopamine in coping with stress. Neurosci. Biobehav. Rev. 2012;36:79–89. doi: 10.1016/j.neubiorev.2011.04.012. PubMed DOI

Van Otterdijk S.D., Mathers J.C., Strathdee G. Do age-related changes in DNA methylation play a role in the development of age-related diseases? Biochem. Soc. Trans. 2013;41:803–807. doi: 10.1042/BST20120358. PubMed DOI

Jung M., Pfeifer G.P. Aging and DNA methylation. BMC Biol. 2015;13:7. doi: 10.1186/s12915-015-0118-4. PubMed DOI PMC

Deans C., Maggert K.A. What Do You Mean, “Epigenetic”? Genetics. 2015;199:887–896. doi: 10.1534/genetics.114.173492. PubMed DOI PMC

Zoghbi H.Y., Beaudet A.L. Epigenetics and Human Disease. Cold Spring Harb. Perspect. Biol. 2016;8:a019497. doi: 10.1101/cshperspect.a019497. PubMed DOI PMC

Tobias D.K., Chavarro J.E., Williams M.A., Buck Louis G.M., Hu F.B., Rich-Edwards J., Missmer S.A., Zhang C. History of Infertility and Risk of Gestational Diabetes Mellitus: A Prospective Analysis of 40,773 Pregnancies. Am. J. Epidemiol. 2013;178:1219–1225. doi: 10.1093/aje/kwt110. PubMed DOI PMC

Kouhkan A., Khamseh M.E., Pirjani R., Moini A., Arabipoor A., Maroufizadeh S., Hosseini R., Baradaran H.R. Obstetric and perinatal outcomes of singleton pregnancies conceived via assisted reproductive technology complicated by gestational diabetes mellitus: A prospective cohort study. BMC Pregnancy Childbirth. 2018;18:495. doi: 10.1186/s12884-018-2115-4. PubMed DOI PMC

Mohammadi M., Morasae E.K., Maroufizadeh S., Almasi-Hashiani A., Navid B., Amini P., Omani-Samani R., Alizadeh A. Assisted reproductive technology and the risk of gestational diabetes mellitus: A systemic review and meta-analysis. Middle East Fertil. Soc. J. 2020;25:6. doi: 10.1186/s43043-020-0018-6. DOI

Cardiovascular Disease-Associated MicroRNAs as Novel Biomarkers of First-Trimester Screening for Gestational Diabetes Mellitus in the Absence of Other Pregnancy-Related Complications

First-Trimester Screening for Fetal Growth Restriction and Small-for-Gestational-Age Pregnancies without Preeclampsia Using Cardiovascular Disease-Associated MicroRNA Biomarkers

Postnatal Expression Profile of MicroRNAs Associated with Cardiovascular Diseases in 3- to 11-Year-Old Preterm-Born Children

Association Analysis in Children Born from Normal and Complicated Pregnancies-Cardiovascular Disease Associated microRNAs and the Incidence of Prehypertension/Hypertension, Overweight/Obesity, Valve Problems and Heart Defects